GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs - GSK (NYSE:GSK), S

GSK plc (NYSE:GSK) and Spero Therapeutics, Inc.

(NASDAQ:SPRO) announced on Wednesday that the U.S.

Food and Drug Administration has approved Utebzi (tebipenem pivoxil hydrobromide), an oral antibiotic for adults with complicated urinary tract infections (cUTIs).

First Oral Carbapenem Approved For This Patient Population The indication includes pyelonephritis, caused by certain susceptible pathogens, and patients who have limited or no alternative oral treatment options.

The companies said Utebzi is the first and only oral carbapenem antibiotic approved for this patient population.